Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedNew trial sites have been added in Heidelberg, Amsterdam, Andalusia, Catalonia, Horta de València, and Madrid. Several previously listed locations were removed.SummaryDifference0.7%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedMinor revision: v3.3.2 replaces v3.2.0; this does not alter any study content or page purpose. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check48 days agoChange DetectedThe government funding/operating status notice at the top of the page has been removed; core study details and eligibility criteria remain unchanged.SummaryDifference0.3%

- Check63 days agoChange DetectedThe updates shown are cosmetic UI/layout changes with no edits to the study's core content (title, NCT ID, interventions, outcomes, or eligibility criteria). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check91 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference3%

- Check99 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.1%

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.